The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 30 | 84.7x | 20.1x | Below average | |
Growth | 87 | 41.5% | 5.6% | Above average | |
Quality | 57 | 28.3% | 7.6% | Near average | |
Safety | 36 | 2.8x | 0.4x | Near average | |
Capital Return | 81 | — | 2.19% | Above average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Xeris Biopharma Holdings, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Xeris Biopharma Holdings, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Our analysis of Xeris Biopharma (XERS) shows a state of complete stability in analyst estimates over the periods (1 day, 7 days, and 30 days ago), with the average price target holding steady at 9 dollars. This consistency reflects a full consensus among the three analysts covering the stock, with zero Dispersion between the high and low price targets, indicating a unified view on the stock's fair value at the current stage.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.